T. Rowe Price Group, Inc. 7.75% NaN 9月 30, 2024 NaN BlackRock, Inc. 6.06% NaN 12月 31, 2024 NaN State Street Global Advisors, Inc. 5.80% NaN 12月 31, 2024 NaN Independent Franchise Partners, LLP 5.78% N ...
T. Rowe Price Group, Inc. 7.75% NaN 9月 30, 2024 NaN BlackRock, Inc. 6.06% NaN 12月 31, 2024 NaN State Street Global Advisors, Inc. 5.80% NaN 12月 31, 2024 NaN Independent Franchise Partners, LLP 5.78% N ...
AA 是一种罕见的胃肠道癌症,发病率低,每 10 万人中约有 1.3 人发病,且属于罕见病范畴,目前尚无 FDA 批准的特效疗法。标准治疗方案为细胞减灭术联合腹腔热灌注化疗(CRS + HIPEC),但并非所有患者都适合手术。传统观念认为 AA 对全身化疗反应不佳,不过近年来,靶向治疗、免疫治疗和腹腔内定向治疗展现出一定潜力。